Evidence map›Paper›PMID 41483304›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Josefin Debus, Isabelle von Götze, Johannes Brandt, Robert Ehehalt, Anna-Maria Spektor, Philipp Mildenberger, Annika Gauss, Matthias Lang, Frederik M Glatting, Mathias Schreckenberger and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Parametric mapping of dynamicCancer imaging : the official publication of the International Cancer Imaging Society · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Josefin DebusDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.ORCID 0009-0006-5346-6965
Isabelle von GötzeDepartment of Nuclear Medicine, University Hospital Mainz, Mainz, Germany.
Johannes BrandtGastroenterology Outpatient Clinic Heidelberg, Heidelberg, Germany.
Robert EhehaltGastroenterology Outpatient Clinic Heidelberg, Heidelberg, Germany.
Anna-Maria SpektorDepartment of Nuclear Medicine, University Hospital Mainz, Mainz, Germany.
Philipp MildenbergerInstitute of Medical Biostatistics, Epidemiology and Informatics, University Medical Centerof the Johannes Gutenberg University, 55131, Mainz, Germany.
Annika GaussDepartment of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Matthias LangDepartment of General, Visceral, and Thoracic Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Frederik M GlattingDepartment of Radiation Oncology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Mathias SchreckenbergerDepartment of Nuclear Medicine, University Hospital Mainz, Mainz, Germany.
Rahul KallaCentre for Inflammation Research, Insititute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK.
Uwe HaberkornDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Manuel RöhrichDepartment of Nuclear Medicine, University Hospital Mainz, Mainz, Germany. manuel.roehrich@unimedizin-mainz.de.ORCID 0000-0001-7609-243X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeInflammatory Bowel Diseases (IBD) comprise ulcerative colitis (UC) and Crohn's disease (CD). Management of IBD requires assessment of disease activity, severity, extent and complications. Here, we describe the signal behavior of both CD and UC in PATIENTS AND

methodsThis analysis includes data of 43 IBD patients and 43 control patients examined by

resultsWe examined 20 CD patients and 23 UC patients (29 with active, 14 with inactive disease). FAPI-uptake in most healthy appearing GI structures of IBD patients was significantly increased compared to controls. Of 80 FAPI-positive GIT-findings, 14 were ruled out as non-IBD related and 66 FAPI-positive IBD lesions were analyzed. We observed equally high lesional FAPI-uptake in CD and UC. All patients with active disease showed at least one intensively FAPI-positive IBD lesion, while only 4/14 patients with inactive disease showed any FAPI-positive IBD lesion. Lesional and patientwise FAPI-uptake was significantly higher in active than in inactive disease. FAPI-positive IBD lesions showed a characteristic kinetic behaviour with two types of uptake patterns - one showing a continuous increase and the other an early peak followed by a plateau.

conclusion

Indexed as

Colitis, UlcerativeCrohn DiseasePositron Emission Tomography Computed TomographyAdultAgedFemaleGallium IsotopesGallium RadioisotopesHumansMaleMiddle AgedQuinolinesYoung Adult68Ga-FAPIGallium IsotopesGallium RadioisotopesQuinolinesCrohn´s diseaseFAPIFibroblastsIBD disease activityUlcerative colitis

Identifiers

PMID41483304
PMCPMC13013222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.